Healthcare services company Astrana Health will be reporting results this Thursday afternoon. Here’s what investors should know.

Astrana Health missed analysts’ revenue expectations last quarter, reporting revenues of $972.5 million, up 48.5% year on year. It was a slower quarter for the company, with full-year revenue guidance slightly missing analysts’ expectations and full-year EBITDA guidance meeting analysts’ expectations.

Is Astrana Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Astrana Health’s revenue to grow 6.8% year on year, slowing from the 99.7% increase it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Astrana Health has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at Astrana Health’s peers in the healthcare technology segment, only Omnicell has reported results so far. It exceeded analysts’ revenue estimates and delivered flat year-on-year revenue. The stock traded up 1.9% on the results.

There has been positive sentiment among investors in the healthcare technology segment, with share prices up 2.8% on average over the last month. Astrana Health is down 2.2% during the same time and is heading into earnings with an average analyst price target of $51.67 (compared to the current share price of $36).

ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.

These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.